NF-γB -: a target in the inflammation of bone destruction

被引:3
|
作者
Doggrell, SA [1 ]
机构
[1] Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia
关键词
bone destruction; inflammation; NEMO-binding domain (NBD) protein; NF-kappa B; rheumatoid arthritis (RA);
D O I
10.1517/14728222.9.1.191
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
NF-kappaB activation is associatied with the inflammation of bone destruction and certain cancers. The NEMO (NF-kB essential modulator)-binding domain (NBD) protein inhibits the activation of NF-kappaB. Cellular studies have shown that the NBD protein inhibits osteoclastogenesis. Mimicking infection with a lipopolysaccharide injection in mice resulted in activated osteoclasts and reduced bone mineral density. These responses are inhibited with the NBD peptide. In a mouse model of rheumatoid arthritis, collagen-induced arthritis, treatment with the NBD protein delayed the onset, lowered the incidence and decreased the severity of the arthritis. NF-kappaB is a target in the inflammation associated with bone destruction. A key issue is whether or not this important transcription factor can be inhibited without causing excessive adverse effects and/or toxicity.
引用
收藏
页码:191 / 193
页数:3
相关论文
共 50 条
  • [21] Chronic inflammation in biomaterial-induced periprosthetic osteolysis: NF-κB as a therapeutic target
    Lin, Tzu-hua
    Tamaki, Yasunobu
    Pajarinen, Jukka
    Waters, Heather A.
    Woo, Deanna K.
    Yao, Zhenyu
    Goodman, Stuart B.
    ACTA BIOMATERIALIA, 2014, 10 (01) : 1 - 10
  • [22] DPHB inhibits osteoclastogenesis by suppressing NF-κB and MAPK signaling and alleviates inflammatory bone destruction
    Liu, Caixia
    Zuo, Min
    Zhao, Jing
    Niu, Tianqi
    Hu, Aihua
    Wang, Hua
    Zeng, Xiangzhou
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2025, 152
  • [23] Inflammation and cancer:: When NF-κB amalgamates the perilous partnership
    Dobrovolskaia, MA
    Kozlov, SV
    CURRENT CANCER DRUG TARGETS, 2005, 5 (05) : 325 - 344
  • [24] NF-κB as an Inducible Regulator of Inflammation in the Central Nervous System
    Anilkumar, Sudha
    Wright-Jin, Elizabeth
    CELLS, 2024, 13 (06)
  • [25] Cancer secretome and inflammation: The bright and the dark sides of NF-κB
    Capece, Darla
    Verzella, Daniela
    Tessitore, Alessandra
    Alesse, Edoardo
    Capalbo, Carlo
    Zazzeroni, Francesca
    SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2018, 78 : 51 - 61
  • [26] NF-κB signaling and bone resorption
    Abu-Amer, Y.
    OSTEOPOROSIS INTERNATIONAL, 2013, 24 (09) : 2377 - 2386
  • [27] NF-κB -: Key mediator of inflammation-associated cancer
    Ditsworth, D
    Zong, WX
    CANCER BIOLOGY & THERAPY, 2004, 3 (12) : 1214 - 1216
  • [28] NF-κB: A Double-Edged Sword Controlling Inflammation
    Liu, Danhui
    Zhong, Zhenyu
    Karin, Michael
    BIOMEDICINES, 2022, 10 (06)
  • [29] The NF-κB pathway as a potential target for autoimmune disease therapy
    Bacher, S
    Schmitz, ML
    CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (23) : 2827 - 2837
  • [30] The complexity of NF-κB signaling in inflammation and cancer
    Bastian Hoesel
    Johannes A Schmid
    Molecular Cancer, 12